BOARD

Founder, Investor & Vice-Chairman
Serial entrepreneur and former. CEO of multiple companies with more than 30 years experience.
Investor; Executive Chairman
Co-founder and Chairman of MedinCell (EPA:MEDCL). Co- founder of Syntro (NASDAQ 1987) and Invitrogen (NASDAQ 1999). Invitrogen was acquired by Thermo Fisher in 2013 for $16bn.

CEO of the Grünenthal Group (€ 1,4B Sales, 4’700 employees in 2019). Previously Company President of AstraZeneca Japan and Germany. Managed brands in immuno-oncology.

Former Head of Manufacturing at Mesoblast (NASDAQ: MESO). Ex- Professor at UTMD Anderson Cancer Center. Led the Cell Therapy Laboratory at UTMD and designed its facility.

SVP Global Clinical Development at Merck KGaA with a strong track record of drug approval (Rebif, Mavenclad). Previously Head of Scientific Affairs and Investor Relations at Serono (listing NYSE)

Non-executive director. Formerly Ambassador to The People’s Republic of China, to Mongolia and the DPRK (2014-2019). Previously Ambassador to France and Monaco (2011-2014).

MANAGEMENT TEAM

CEO 

Serial entrepreneur and former. CEO of multiple companies with more than 30 years experience.

CTO
Over 40 years of experience in the pharmaceutical and healthcare industry. Founder of several biotechnology start-ups
CFO
Manager with experience in start-ups and biotech (Celgene). HEC, HSG & EPFL training.

SCIENTIFIC & BUSINESS ADVISORS

Scientific Advisor
Professor of neurosciences. Former dean of KAUST, professor at EPFL.
Scientific Advisor
Head of the IRMB, the Institute for Regenerative Medicine and Biotherapy based in Montpellier
Business Advisor
Strategic consultant with extensive experience in healthcare and cell therapy. Former Partner and Managing Director at the Boston Consulting Group. Previously EVP, COO at Cellectis.